What it's for (Indications)
- Terazosin HCl is a selective alpha-1 adrenergic receptor antagonist indicated for the management of two primary conditions.
- Firstly, it is prescribed for the treatment of **Benign Prostatic Hyperplasia (BPH)**, a non-cancerous enlargement of the prostate gland.
- In patients with BPH, terazosin helps to alleviate bothersome lower urinary tract symptoms (LUTS) such as weak stream, hesitancy, urgency, and frequent urination, by relaxing the smooth muscles in the prostate and bladder neck, thereby improving urine flow.
- This pharmacological action reduces urethral resistance, leading to enhanced bladder emptying.
- Secondly, it is indicated for the treatment of **hypertension**, either alone as monotherapy or in combination with other antihypertensive agents as part of a multi-drug regimen.
- By blocking alpha-1 receptors primarily located on vascular smooth muscle, terazosin promotes peripheral vasodilation, leading to a reduction in systemic vascular resistance and, consequently, a lowering of both systolic and diastolic blood pressure.
- Its efficacy and safety profile in both these therapeutic areas have been well-established through extensive clinical trials.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For both hypertension and benign prostatic hyperplasia (BPH), the initial recommended dosage of terazosin HCl is 1 mg administered orally once daily at bedtime. This specific timing of administration is crucial to mitigate the pronounced 'first-dose effect,' which can lead to significant orthostatic hypotension and syncope. Subsequent dosage titration should be gradual and individualized based on the patient's clinical response and tolerability, as well as the specific condition being treated. For hypertension, the dose may be gradually increased over several weeks to 2 mg, 5 mg, or 10 mg once daily, and if necessary, up to a maximum of 20 mg once daily, to achieve the desired blood pressure control. For BPH, the typical maintenance doses range from 5 mg to 10 mg once daily, with the maximum usually not exceeding 20 mg daily. Patients should be carefully monitored for hypotensive symptoms, particularly dizziness and lightheadedness, during dose escalation, and advised to avoid sudden changes in posture. If terazosin administration is interrupted for several days or longer, therapy should be re-initiated with the 1 mg dose. |
Safety & Warnings
Common Side Effects
- Terazosin HCl, while effective in its indications, is associated with a range of side effects, primarily related to its vasodilatory action and alpha-1 adrenergic blockade.
- Common side effects reported by patients include dizziness, lightheadedness, headache, asthenia (generalized weakness or lack of energy), nasal congestion, palpitations, nausea, and peripheral edema.
- Somnolence (drowsiness) is also frequently observed, particularly with initial doses or dose increases, reinforcing the recommendation for bedtime administration.
- More serious, though less common, side effects include marked orthostatic hypotension and syncope (fainting), especially following the first dose, upon re-initiation, or during rapid dose escalation.
- Other serious but rare adverse events include priapism (a prolonged and painful erection unrelated to sexual stimulation, which constitutes a urological emergency and requires immediate medical attention to prevent permanent erectile dysfunction), and Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.
- Patients should be thoroughly educated on recognizing these symptoms and seeking appropriate medical advice promptly.
- Allergic reactions, though rare, can also occur.
Serious Warnings
- Black Box Warning: Terazosin HCl does **not** carry a specific FDA Black Box Warning. However, due to its significant potential for adverse effects, particularly related to its vasodilatory properties, a serious warnings section is imperative. **Serious Warnings:** The most critical concern with terazosin HCl therapy is the potential for **marked orthostatic hypotension and syncope (fainting)**, especially with the initial dose, following re-initiation after a period of interruption, or during dosage escalation. This phenomenon, often referred to as the 'first-dose effect,' can lead to dizziness, lightheadedness, and potentially falls and associated injuries, particularly in elderly or frail patients. Patients should be explicitly warned about this risk and advised to take the first dose at bedtime, avoid situations where injury could result from syncope for the first 12 hours after the initial dose or dose increase, and to rise slowly from a seated or supine position. Concomitant use with other antihypertensive agents, especially phosphodiesterase-5 (PDE5) inhibitors for erectile dysfunction (e.g., sildenafil, tadalafil), significantly increases the risk of symptomatic hypotension and should be undertaken with extreme caution, often requiring dose adjustments of both medications and diligent blood pressure monitoring. Furthermore, rare but serious cases of **priapism** (a prolonged, painful erection lasting more than 4 hours and unrelated to sexual stimulation) have been reported, necessitating immediate medical attention to prevent permanent erectile dysfunction. Patients should also be advised to inform their ophthalmologist of current or past terazosin use if they are scheduled for cataract surgery, due to the risk of **Intraoperative Floppy Iris Syndrome (IFIS)**, which can complicate the surgical procedure. These warnings underscore the importance of careful patient education, appropriate dosing, and diligent monitoring throughout therapy to ensure patient safety.
- Several significant warnings are associated with terazosin HCl therapy, primarily due to its pharmacological effects.
- The most critical is the potential for **orthostatic hypotension** and **syncope (fainting)**, often referred to as the 'first-dose effect.
- ' This risk is highest with the initial dose, upon reintroduction after a period of discontinuation, or following dose increases.
- Patients should be explicitly advised to take the first dose at bedtime and exercise extreme caution when changing positions rapidly (e.
- g.
- , rising from a seated or lying position) to minimize the risk of falls and injury.
- Concomitant administration with other antihypertensive agents, especially phosphodiesterase-5 (PDE5) inhibitors (e.
- g.
- , sildenafil, tadalafil) for erectile dysfunction, can significantly potentiate hypotensive effects and should be approached with extreme caution, often requiring dose adjustments of both medications and careful monitoring.
- **Priapism**, a rare but serious urological emergency, has been reported; patients should be counselled to seek immediate medical attention for any erection lasting longer than 4 hours to prevent permanent tissue damage.
- Furthermore, **Intraoperative Floppy Iris Syndrome (IFIS)** has been observed during cataract surgery in patients currently or previously treated with alpha-1 blockers.
- Therefore, ophthalmologists should be informed of current or past terazosin use prior to surgical procedures.
- Patients engaged in hazardous activities, such as operating heavy machinery or driving, should be warned about potential dizziness or somnolence, particularly at the initiation of therapy or following dose adjustments.
- Use in patients with severe hepatic impairment requires caution and careful monitoring due to altered drug metabolism.
How it Works (Mechanism of Action)
Terazosin HCl functions as a potent and highly selective competitive antagonist of alpha-1 adrenergic receptors located in various tissues throughout the body. Its therapeutic effects stem from blocking these receptors. In the context of benign prostatic hyperplasia (BPH), alpha-1 receptors are predominantly found in the smooth muscle of the prostate gland, prostatic capsule, and bladder neck. By blocking these receptors, terazosin induces relaxation of the smooth muscle tone in these areas, consequently reducing the dynamic component of bladder outflow obstruction. This leads to a decrease in urethral resistance and an improvement in urine flow, thereby alleviating the bothersome lower urinary tract symptoms associated with BPH, such as hesitancy, weak stream, and nocturia. For its antihypertensive effect, terazosin targets alpha-1 receptors present on vascular smooth muscle cells in both arterioles and venules. Antagonism of these receptors results in peripheral vasodilation, reducing systemic vascular resistance and venous return, which ultimately leads to a decrease in arterial blood pressure. The selective nature of its alpha-1 antagonism distinguishes it from non-selective alpha blockers, contributing to its specific therapeutic profile with potentially fewer central nervous system side effects.